Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + Genexol-PM
- Development stage
- Unknown
- Lead developer
- Samyang Biopharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
doxorubicin + Genexol-PM is a combination chemotherapy regimen consisting of the anthracycline doxorubicin and Genexol-PM, a Cremophor EL-free, polymeric micellar formulation of paclitaxel. Developed by Samyang Biopharmaceuticals, Genexol-PM utilizes a biodegradable amphiphilic diblock copolymer (mPEG-PDLLA) drug delivery vehicle to encapsulate paclitaxel, forming stable micelles that improve solubility and reduce the hypersensitivity risks associated with traditional paclitaxel formulations. Doxorubicin acts by intercalating DNA and inhibiting topoisomerase II, which leads to DNA strand breaks and cell death. Paclitaxel, the active ingredient in Genexol-PM, stabilizes microtubules to inhibit their disassembly, thereby arresting the cell cycle in the G2/M phase. This combination has been evaluated in Phase II clinical trials by Gachon University Gil Medical Center for the treatment of advanced or metastatic HER2-negative breast cancer, demonstrating significant objective response rates.
- Brand names
- Genexol-PM
- Other names
- doxorubicin and Genexol-PMGenexol-PM/doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on doxorubicin + Genexol-PM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + Genexol-PM.